1/14
07:36 pm
sls
A Look At SELLAS Life Sciences Group (SLS) Valuation After New IMPACT AML Clinical Study Agreement [Yahoo! Finance]
Medium
Report
A Look At SELLAS Life Sciences Group (SLS) Valuation After New IMPACT AML Clinical Study Agreement [Yahoo! Finance]
1/14
08:30 am
sls
SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe
Low
Report
SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe
1/6
08:27 am
sls
SELLAS Life Sciences Group (SLS) Is Up 50.8% After REGAL Trial Nears Final OS Trigger - Has The Bull Case Changed? [Yahoo! Finance]
High
Report
SELLAS Life Sciences Group (SLS) Is Up 50.8% After REGAL Trial Nears Final OS Trigger - Has The Bull Case Changed? [Yahoo! Finance]
12/29
09:02 am
sls
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) [Yahoo! Finance]
High
Report
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) [Yahoo! Finance]
12/29
08:35 am
sls
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)
High
Report
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)
12/25
11:47 am
sls
Assessing SELLAS Life Sciences Group (SLS) Valuation After Positive Leukemia Data and Supportive FDA Designations [Yahoo! Finance]
Low
Report
Assessing SELLAS Life Sciences Group (SLS) Valuation After Positive Leukemia Data and Supportive FDA Designations [Yahoo! Finance]
12/10
10:38 pm
sls
Why SELLAS Life Sciences Group (SLS) Is Up 12.6% After Encouraging SLS009 Phase 2 AML Data And What's Next [Yahoo! Finance]
Low
Report
Why SELLAS Life Sciences Group (SLS) Is Up 12.6% After Encouraging SLS009 Phase 2 AML Data And What's Next [Yahoo! Finance]
12/7
06:00 pm
sls
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025
Low
Report
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025
11/12
04:53 pm
sls
SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/12
04:05 pm
sls
SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Medium
Report
SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/3
09:00 am
sls
SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting
Low
Report
SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting
10/27
08:30 am
sls
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds
Medium
Report
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds
10/22
09:00 am
sls
SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum
Low
Report
SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum